Paper Details

  1. Home
  2. Paper Details

Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.

Author: ArmstrongApril W, BanerjeeSubhashis, BlauveltAndrew, ColstonElizabeth, GooderhamMelinda, ImafukuShinichi, KunduSudeep, LinaberryMisti, MoritaAkimichi, PappKim A, SchoenfeldSteve, StroberBruce, SzepietowskiJacek C, ThaçiDiamant, ThroupJohn, WarrenRichard B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Deucravacitinib is a new treatment for plaque psoriasis, a skin condition that causes round or oval raised patches (called plaques) typically covered by scales. This can cause itching, cracking, and bleeding, making it difficult to perform basic tasks. While treatments are available, some are ineffective, inconvenient, or have side effects. Researchers are looking for new treatments that are more effective, convenient, and safe.
Paper Details　
Original Abstract of the Article :
This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/imt-2023-0061

データ提供：米国国立医学図書館（NLM）

Deucravacitinib for Plaque Psoriasis: A Plain Language Summary

Psoriasis, a chronic inflammatory skin condition, can be a challenging and frustrating condition. This study, like a beacon of hope in the desert of psoriasis research, examines the effectiveness of a new treatment called deucravacitinib for plaque psoriasis. The authors provide a clear and concise summary of the results of a clinical trial called POETYK PSO-1, highlighting the potential benefits and safety of this novel treatment.

A New Frontier in Psoriasis Treatment

The study found that deucravacitinib was effective in reducing the symptoms of plaque psoriasis. The medication was shown to significantly improve skin clearance and reduce itching and pain associated with the condition.

Navigating the Path to Relief

The authors emphasize that deucravacitinib was well-tolerated by patients in the study. The medication was associated with a manageable side effect profile, making it a promising new option for patients seeking relief from plaque psoriasis.

Dr. Camel's Conclusion

This study, like a refreshing spring in the desert of psoriasis research, offers hope for patients seeking effective and safe treatment options. The findings suggest that deucravacitinib may be a valuable addition to the therapeutic arsenal for managing plaque psoriasis.

Date :
  1. Date Completed 2023-07-14
  2. Date Revised 2023-07-18
Further Info :

Pubmed ID

37150952

DOI: Digital Object Identifier

10.2217/imt-2023-0061

Related Literature

Article Analysis
・Effects of deucravacitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.